Home Current Issue Previous Issues Published Ahead-of-Print For Authors Journal Info
Skip Navigation LinksHome > January 2005 - Volume 45 - Issue 1 > Renin-Angiotensin System Intervention to Prevent In-Stent Re...
Text sizing:
A
A
A
Journal of Cardiovascular Pharmacology:
Review Article

Renin-Angiotensin System Intervention to Prevent In-Stent Restenosis: An Unclosed Chapter

Langeveld, Bas MD*; Roks, Anton J. M. PhD*; Tio, Rene A. MD, PhD†; Voors, Adriaan A. MD, PhD†; Zijlstra, Felix MD, PhD†; van Gilst, Wiek H. PhD*

Collapse Box

Abstract

The occurrence of in-stent restenosis is a major drawback of percutaneous transluminal coronary angioplasty with stent placement. Target vessel revascularization is necessary in 15% of patients who receive a stent. Recent advances in the development of drug-eluting stents have reduced these numbers tremendously. However refinement of antirestenotic therapies remains obligatory. The emerging interest in more physiological antirestenotic therapies might unchain an interest in the well-known inhibitors of the rennin-angiotensin system (RAS), the angiotensin-converting enzyme inhibitors, and the angiotensin II type I receptor blockers. Contradictory results overshadow the discussion of whether intervention in the RAS could prevent in-stent restenosis. This review discusses the pathophysiology of in-stent restenosis, the role of the RAS in in-stent restenosis, and the possible role of RAS intervention in the prevention of in-stent restenosis.

© 2005 Lippincott Williams & Wilkins, Inc.

Follow Us!

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.